Outlook Therapeutics downgraded by Guggenheim
$OTLK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim downgraded Outlook Therapeutics from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2024 | $50.00 | Neutral → Buy | BTIG Research |
| 2/15/2024 | $3.00 | Neutral → Buy | Chardan Capital Markets |
| 1/25/2024 | Neutral → Buy | Guggenheim | |
| 12/27/2023 | $5.00 | Equal Weight → Overweight | CapitalOne |
| 8/31/2023 | $5.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
| 8/31/2023 | Buy → Neutral | Chardan Capital Markets | |
| 8/30/2023 | Overweight → Equal Weight | CapitalOne | |
| 8/30/2023 | Buy → Neutral | Guggenheim |
European Commission Approval Followed By Anticipated EU And UK Launches In Q1 2025; Strategic Partnership With Cencora To Support Launch
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $30 price target.
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat on Tuesday, November 12, 2024 at 2:30 PM ET at the Guggenheim Healthcare Innovation Conference being held in Boston, MA. In addition to the fireside chat, management will be available to participate in one-on-one in-person m
Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics participated in a Virtual Investor CEO Connect segment. As part of this segment, Mr. Trenary provided an overview of the Company's recent accomplishments and highlighted near-term value driving milestones as the Company wor
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in the Virtual Investor Closing Bell Series on Thursday, September 19, 2024 at 4:00 PM ET. As part of the event, Mr. Trenary will provide a corporate overview and business outlook. In addition to the prepared remarks, there will be a live que
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
BTIG Research upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $50.00
Chardan Capital Markets upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $3.00
Guggenheim upgraded Outlook Therapeutics from Neutral to Buy
Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMDNORSE EIGHT current enrollment pace supports topline readout target of Q4 CY2024Resubmission of the ONS-5010 Biologics License Application (BLA) on track for Q1 CY2025Quarterly update conference call and webcast today, Wednesday, August 14th at 8:30 AM ET ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degenerati
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that it will report its financial results for third quarter fiscal year 2024 on Wednesday, August 14, 2024. Outlook Therapeutics management will host its quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day. The call will be led by Russell Trenary, President and Chief Executive Officer and Lawrence Kenyon, Chief Financial Officer
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma)United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the US; Topline readout expected in Q4 CY2024Resubmission of the ONS-5010 Biologics License Application (BLA) planned by the end of CY2024 Company to host inaugural quarterly update conference call and webcast on Thursday, May 16th at 8:30 AM ET ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized
SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)
S-8 - Outlook Therapeutics, Inc. (0001649989) (Filer)
10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)
8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)
ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe. Mr. Comiskey has a successful track record in the planning, organization and execution of product launches. Over the course of his career, he has demonstrated innovative, solution-focused results, navigating the highly complex European pharmaceutical landscape. "We believe in the potential of ONS-5010 to address the global need for an approved bevacizumab that meets ophtha
ISELIN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Julia A. Haller, MD, to the Company's Board of Directors. "We are pleased to welcome Dr. Haller to Outlook Therapeutics' Board of Directors. As one of the world's most accomplished professionals in ophthalmic education, research, and clinical ophthalmic practice, she will add tremendous value and insight to Outlook Therapeutics," said Randy Thurman, Executive Chairman of the Outlook Therapeutics Board o
Ms. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with deep experience in ophthalmology and leadership for launching wet AMD/DME therapies. ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access. "We are pleased to strengthen our commercialization expertise with the addition of Alicia to our leader
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)
4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)